Butylene glycol laurate | 180680-00-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Butylene glycol laurate
• 英文别名: 2-hydroxybutyl dodecanoate
• CAS: 180680-00-6
• 化学式: C₁₆H₃₂O₃
• 分子量: 272.42
• InChiKey: OVFAVSHTEIQRPQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  19
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Methods and compositions to treat glycosaminoglycan-associated molecular interactions
  申请人：Kisilevsky Robert

  公开号：US20070078082A1

  公开（公告）日：2007-04-05

  Therapeutic compounds and methods for inhibiting a glycosaminoglycan (GAG)-associated molecular interaction in a subject, whatever its clinical setting, are described
• Phosphono-carboxylate compounds for treating amyloidosis
  申请人：Szarek A. Walter

  公开号：US20080004244A1

  公开（公告）日：2008-01-03

  Therapeutic compounds and methods for modulating amyloid deposition in a subject, whatever its clinical setting, are described. Amyloid deposition is modulated by the administration to a subject of an effective amount of a therapeutic compound comprising a phosphonate group and a carboxylate group, a congener thereof, or a pharmaceutically acceptable salt or ester thereof. In preferred embodiments, an interaction between an amyloidogenic protein and a basement membrane constituent is modulated.
• Methods for modulating neuronal cell death
  申请人：Gervais Francine

  公开号：US20080249184A1

  公开（公告）日：2008-10-09

  The invention provides methods of inhibiting Aβ-induced neuronal cell death. The invention further provides methods of providing neuroprotection to a subject and methods of treating a disease state characterized by Aβ-induced neuronal cell death in a subject. Methods of inhibiting p75 receptor mediated neuronal cell death, as well as methods of treating a disease state in a subject characterized by p75 receptor mediated neuronal cell death are provided.
• Compounds and methods for modulating cerebral amyloid angiopathy
  申请人：Green Allan M.

  公开号：US20080317834A1

  公开（公告）日：2008-12-25

  The invention provides methods of inhibiting cerebral amyloid angiopathy. The invention further provides methods of treating a disease state characterized by cerebral amyloid angiopathy in a subject.